TY - JOUR
T1 - Outcomes registry for better informed treatment of atrial fibrillation II
T2 - Rationale and design of the ORBIT-AF II registry
AU - Steinberg, Benjamin A.
AU - Blanco, Rosalia G.
AU - Ollis, Donna
AU - Kim, Sunghee
AU - Holmes, Dajuanicia N.
AU - Kowey, Peter R.
AU - Fonarow, Gregg C.
AU - Ansell, Jack
AU - Gersh, Bernard
AU - Go, Alan S.
AU - Hylek, Elaine
AU - Mahaffey, Kenneth W.
AU - Thomas, Laine
AU - Chang, Paul
AU - Peterson, Eric D.
AU - Piccini, Jonathan P.
N1 - Funding Information:
The ORBIT-AF II registry is sponsored by Janssen Scientific Affairs, LLC, Raritan, NJ. Dr Steinberg was funded by National Institutes of Health T-32 Training Grant No. 5 T32 HL 7101-38 .
PY - 2014/8
Y1 - 2014/8
N2 - Background Recent clinical trials have demonstrated the safety and efficacy of several non-vitamin K oral anticoagulants (NOACs) for the treatment of atrial fibrillation (AF). However, there are limited data on their use and outcomes in routine clinical practice, particularly among patients newly diagnosed as having AF and patients with AF recently transitioned to a NOAC. Methods/Design ORBIT-AF II is a multicenter, national registry of patients with AF that is enrolling up to 15,000 newly diagnosed patients with AF and/or those with AF recently transitioned to a NOAC from 300 US outpatient practices. These patients will be followed for up to 2 years, including clinical status, outcomes (major adverse cardiovascular events, bleeding), and management of anticoagulation surrounding bleeding events. In addition, detailed data regarding the use of these agents in and around cardiac procedures, their complications, and management of such complications will be collected. Conclusions The ORBIT-AF II registry will provide valuable insights into the safety and effectiveness of NOACs used in AF in community practice settings.
AB - Background Recent clinical trials have demonstrated the safety and efficacy of several non-vitamin K oral anticoagulants (NOACs) for the treatment of atrial fibrillation (AF). However, there are limited data on their use and outcomes in routine clinical practice, particularly among patients newly diagnosed as having AF and patients with AF recently transitioned to a NOAC. Methods/Design ORBIT-AF II is a multicenter, national registry of patients with AF that is enrolling up to 15,000 newly diagnosed patients with AF and/or those with AF recently transitioned to a NOAC from 300 US outpatient practices. These patients will be followed for up to 2 years, including clinical status, outcomes (major adverse cardiovascular events, bleeding), and management of anticoagulation surrounding bleeding events. In addition, detailed data regarding the use of these agents in and around cardiac procedures, their complications, and management of such complications will be collected. Conclusions The ORBIT-AF II registry will provide valuable insights into the safety and effectiveness of NOACs used in AF in community practice settings.
UR - http://www.scopus.com/inward/record.url?scp=84905097597&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905097597&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2014.04.005
DO - 10.1016/j.ahj.2014.04.005
M3 - Article
C2 - 25066554
AN - SCOPUS:84905097597
SN - 0002-8703
VL - 168
SP - 160
EP - 167
JO - American heart journal
JF - American heart journal
IS - 2
ER -